Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio

针对 Presentio 宿主同种抗原特异性的供体 Tregs 的过继转移

基本信息

  • 批准号:
    8563670
  • 负责人:
  • 金额:
    $ 46.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Graft-versus-host disease (GVHD) is the main cause of stem cell transplant-related mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Regulatory T cells prevent GVHD in preclinical models and early trials. Adoptive transfer of poly-specific Tregs exploits their natural suppressive functions and aims to alter the in vivo balance of T effectors and Tregs. However, this approach may also produce the same broad immunosuppressive effects that are caused by drugs. Experimental rodent models from our lab and others demonstrate that alloantigen-specific Tregs are more effective at preventing GVHD and improving survival than polyspecific Tregs. Our Long-Term Goal is to exploit Tregs to prevent GVHD in humans without suppressing desirable immune responses against infectious pathogens or malignant cells. Given their low frequency in human blood, several groups have explored ex-vivo Treg expansion for therapeutic application and these expanded Tregs retain suppressive activity. In contrast to polyspecific Tregs expanded non-selectively, antigen-specific Tregs produce selective suppression of allo-responses with no effect on third-party responses and facilitate alloantigen-specific tolerance after HSCT and organ grafting in. Before these results find clinical application, early clinical studies are required to address scientific and mechanistic questions and move the field forward. Our central hypothesis is that donor Tregs specific for host alloantigens presented by dendritic cells will prevent GVHD more effectively than current standard immune suppressive drugs, while preserving immunity to viral pathogens and cancer-associated antigens. The objective of this application is to conduct a first-in-human Phase I adoptive immunotherapy trial of allo-specific Tregs for GVHD prevention after HLA- identical sibling HSCT. Important to the potential application of Tregs to human HSCT, is the development of an immune suppressive platform containing rapamycin that selectively permits survival, expansion and suppressive function of Tregs while inhibiting other effector T cells. By trace-labeling the Tregs, we will also assess Treg repopulation and survival after adoptive transfer to allograft recipients.
描述(申请人提供):移植物抗宿主病(GVHD)是异基因造血干细胞移植(HSCT)后干细胞移植相关死亡的主要原因。调节性T细胞在临床前模型和早期试验中预防GVHD。多特异性Tregs的过继转移利用了它们的自然抑制功能,目的是改变体内T效应器和Tregs的平衡。然而,这种方法也可能产生与药物相同的广泛免疫抑制效应。我们实验室和其他实验室的实验啮齿动物模型表明,同种异体抗原特异性Tregs在预防GVHD和提高存活率方面比多特异性Tregs更有效。我们的长期目标是利用Tregs来预防人类的GVHD,而不会抑制对感染病原体或恶性细胞的理想免疫反应。鉴于它们在人类血液中的频率很低,几个小组已经探索了体外Treg扩展用于治疗应用,这些扩展的Treg保留了抑制活性。与非选择性扩增的多特异性Tregs不同,抗原特异性Tregs可选择性抑制同种异体反应,而对第三方反应无影响,并促进HSCT和器官移植后的同种异体抗原特异性耐受。在这些结果得到临床应用之前,需要进行早期临床研究,以解决科学和机械问题,并推动该领域的发展。我们的中心假设是,树突状细胞呈递的针对宿主同种异体抗原的供体Tregs将比目前的标准免疫抑制药物更有效地预防GVHD,同时保持对病毒病原体和癌症相关抗原的免疫力。这项应用的目的是进行人类首个同种特异性Tregs的I期过继免疫治疗试验,用于预防HLA相合同胞HSCT后的GVHD。对于Tregs在人类造血干细胞移植中的潜在应用来说,重要的是开发一种含有雷帕霉素的免疫抑制平台,该平台选择性地允许Tregs的生存、扩增和抑制功能,同时抑制其他效应性T细胞。通过跟踪标记Treg,我们还将评估Treg的再繁殖和过继移植到同种异体移植受体后的存活率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLAUDIO ANASETTI其他文献

CLAUDIO ANASETTI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLAUDIO ANASETTI', 18)}}的其他基金

Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio
针对 Presentio 宿主同种抗原特异性的供体 Tregs 的过继转移
  • 批准号:
    8710334
  • 财政年份:
    2013
  • 资助金额:
    $ 46.83万
  • 项目类别:
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio
针对 Presentio 宿主同种抗原特异性的供体 Tregs 的过继转移
  • 批准号:
    8840492
  • 财政年份:
    2013
  • 资助金额:
    $ 46.83万
  • 项目类别:
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio
针对 Presentio 宿主同种抗原特异性的供体 Tregs 的过继转移
  • 批准号:
    9059174
  • 财政年份:
    2013
  • 资助金额:
    $ 46.83万
  • 项目类别:
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*
血液和骨髓移植临床试验网络 (BMT CTN) - 核心临床 C*
  • 批准号:
    8485654
  • 财政年份:
    2011
  • 资助金额:
    $ 46.83万
  • 项目类别:
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*
血液和骨髓移植临床试验网络 (BMT CTN) - 核心临床 C*
  • 批准号:
    8316236
  • 财政年份:
    2011
  • 资助金额:
    $ 46.83万
  • 项目类别:
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*
血液和骨髓移植临床试验网络 (BMT CTN) - 核心临床 C*
  • 批准号:
    8678987
  • 财政年份:
    2011
  • 资助金额:
    $ 46.83万
  • 项目类别:
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*
血液和骨髓移植临床试验网络 (BMT CTN) - 核心临床 C*
  • 批准号:
    8165426
  • 财政年份:
    2011
  • 资助金额:
    $ 46.83万
  • 项目类别:
Peripheral T Cell tolerance by targeting AKT
通过靶向 AKT 实现外周 T 细胞耐受
  • 批准号:
    7643550
  • 财政年份:
    2009
  • 资助金额:
    $ 46.83万
  • 项目类别:
Peripheral T Cell tolerance by targeting AKT
通过靶向 AKT 实现外周 T 细胞耐受
  • 批准号:
    7842641
  • 财政年份:
    2009
  • 资助金额:
    $ 46.83万
  • 项目类别:
Antigen Specific T Cell tolerance by Anti CD3 Antibodies
抗 CD3 抗体的抗原特异性 T 细胞耐受
  • 批准号:
    8120238
  • 财政年份:
    2008
  • 资助金额:
    $ 46.83万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.83万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了